C12Y 302/01076
L-iduronidase
Official title: L-Iduronidase (3.2.1.76)
C12Y302/01076 (L-iduronidase) appears on 72 US grants and 171 published applications in this corpus.
Search patents in C12Y- Granted patents
- 72
- Published applications
- 171
- Assignees
- 66
- Inventors
- 269
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1999 | 3 | 0 |
| 2000 | 1 | 0 |
| 2001 | 2 | 1 |
| 2002 | 1 | 4 |
| 2003 | 3 | 1 |
| 2004 | 0 | 3 |
| 2005 | 1 | 4 |
| 2006 | 2 | 4 |
| 2007 | 0 | 2 |
| 2008 | 1 | 1 |
| 2009 | 1 | 3 |
| 2010 | 0 | 4 |
| 2011 | 1 | 0 |
| 2012 | 1 | 2 |
| 2013 | 2 | 2 |
| 2014 | 1 | 4 |
| 2015 | 5 | 7 |
| 2016 | 2 | 8 |
| 2017 | 5 | 5 |
| 2018 | 4 | 17 |
| 2019 | 6 | 15 |
| 2020 | 8 | 8 |
| 2021 | 6 | 13 |
| 2022 | 5 | 12 |
| 2023 | 1 | 19 |
| 2024 | 7 | 12 |
| 2025 | 2 | 14 |
| 2026 | 1 | 6 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Targeting the human CCR5 locus as a safe harbor for the expression of therapeutic proteins15 Sep 2026US 12,735,711 B2The Board of Trustees of the Leland Stanford Junior University
- Plant lectins as carriers of associated drug substances into animal and human cells15 Apr 2025US 12,275,968 B2Biostrategies Lc
- AAV-IDUA vector for treatment of MPS I-associated blindness21 Jan 2025US 12,201,697 B2The University of North Carolina at Chapel Hill
- Methods and compositions for the treatment of steatosis-associated disorders24 Dec 2024US 12,171,731 B2Duke University
- Methods to treat mucopolysaccharidosis type II or deficiency in iduronate-2-sulfatase using a recombinant adeno-associated virus (AAV) vector encoding iduronate-2-sulfatase22 Oct 2024US 12,121,567 B2Regents of the University of Minnesota
- Methods of increasing sialic acid levels in recombinant glycosylated proteins8 Oct 2026US 2026/0308601 A1Denali Therapeutics Inc.
- Aav9-mediated gene therapy for treating mucopolysaccharidosis type i24 Sep 2026US 2026/0284155 A1The Trustees of the University of Pennsylvania
- Method for improving neurological function in mpsi and mpsii and other neurological disorders20 Aug 2026US 2026/0241038 A1Regents of the University of Minnesota
- Anti-Human Transferrin Receptor Antibody Permeating Blood-Brain Barrier2 Jul 2026US 2026/0184781 A1JCR Pharmaceuticals Co., Ltd.
- Compositions and methods comprising programmable snrnas for rna editing28 May 2026US 2026/0144893 A1Regeneron Pharmaceuticals, Inc.
Most cited
By later US patents
- Biocompatible implant for the expression and in vivo secretion of a therapeutic substance151US 5,906,817 AInstitut Pasteur · 1999
- Production of lysosomal enzymes in plant-based expression systems117US 5,929,304 ACroptech Development Corporation · 1999
- Intranasal delivery of AAV encoding therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases78US 9,249,424 B2HealthPartners Research & Education · 2016
- MAPC administration for the treatment of lysosomal storage disorders50US 7,927,587 B2Regents of the University of Minnesota · 2011
- Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof40US 6,569,661 B1Biomarin Pharmaceutical Inc. · 2003